image description

Former Congressman Dr. Phil Gingrey provides public policy and government relations counsel to clients on a variety of issues. Here at Phil on the Hill, Phil draws upon his long career in public service to provide perspective and context on policy topics such as health care, the federal budget, annual appropriations, regulatory reform, and life sciences.



Don't be penny wise, pound foolish with 340B drug pricing program

Monday, July 09, 2018

Earlier this year, the Trump administration ordered the Centers for Medicare and Medicaid (CMS) to reduce 340B Drug Pricing Program payments to hospitals by nearly 30 percent. The program requires drug manufacturers to sell outpatient drugs at discounts to hospitals and health care providers that serve a significant number of low-income patients, with no cost to taxpayers. These hospitals and health care providers have used the cost savings to reach more patients and provide more comprehensive services, so these cuts will have a deep impact on communities.

In my latest op-ed for The Hill, I provide my perspective on why these cuts are foolish and how the 340B program saves money for our broader health care system.

Read: Don't be penny wise, pound foolish with 340B drug pricing program